Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations.

Cancer treatment and research communications - 1 Jan 2024

Ho Jason C S, Cheung K M

Abstract excerpt

Unresectable stage III non-small cell lung cancer (NSCLC) carries a poor prognosis. The PACIFIC trial established consolidation durvalumab after chemoradiation as a standard treatment; however, its efficacy in patients with driver mutations remains uncertain. This retrospective cohort study analyzed data from three oncology centers in Hong Kong, covering the period from January 2019 to December 2022. Among the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antibodies, Monoclonal
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to ROS1 gene

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 39808885
DOI: 10.1016/j.ctarc.2025.100863

Genes

ALK
EGFR
RET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations.PMID 39808885Read ↗

Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.Semantic proximity Read ↗

Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).Semantic proximity Read ↗

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.Semantic proximity Read ↗

Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer.Semantic proximity Read ↗

Comparison of efficacy and safety of first-line treatment options for unresectable stage III non-small cell lung cancer: a retrospective analysisSemantic proximity Read ↗

Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancersSemantic proximity Read ↗

Equalizing prognostic disparities in stage III KRAS-mutant NSCLC: addition of durvalumab to combined chemoradiotherapy improves survivalSemantic proximity Read ↗

Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.Semantic proximity Read ↗

Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration.Semantic proximity Read ↗

A Study on the Efficacy of Immune Checkpoint Inhibitors Combined with Chemotherapy in Patients with Oligometastatic Driver Gene-Negative Non-Small Cell Lung Cancer Undergoing RadiotherapySemantic proximity Read ↗

Treatment Patterns and Clinical Outcomes in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer in China.Semantic proximity Read ↗

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.